Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed this Form 8-K under Item 8.01 (Other Events) regarding its continued noncompliance with Nasdaq’s minimum bid price requirement. The report date was February 28, 2023, and the filing was signed on March 2, 2023.
The Company’s common stock trades under the symbol UNCY on the Nasdaq Capital Market. Unicycive is incorporated in Delaware and reported that it qualifies as an emerging growth company.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement metrics. It states that the Company did not meet Nasdaq’s $5.0 million stockholders’ equity initial listing requirement for The Nasdaq Capital Market.
Material Changes Versus the Prior Comparable Period
- On August 8, 2022, Nasdaq notified the Company that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days.
- On February 1, 2023, Nasdaq determined that the Company had not regained compliance and was not eligible for a second 180-day compliance period because it did not satisfy the $5.0 million stockholders’ equity requirement.
- On February 28, 2023, following the Company’s hearing request, Nasdaq granted an exception through July 24, 2023 to complete a reverse stock split, if necessary, and subsequently regain compliance with the minimum bid price rule.
Guidance, Outlook, Risks, and Unusual Items
The Company received additional time, rather than a waiver, to address the Nasdaq deficiency. It may need to effect a reverse stock split by July 24, 2023 and must thereafter regain compliance with Nasdaq Listing Rule 5550(a)(2).
Failure to satisfy the requirements within the exception period could result in delisting proceedings or loss of Nasdaq Capital Market listing. The filing does not state whether a reverse stock split will occur, its potential ratio, or the Company’s expected effect on stockholders.
Investor Verification Points
- Verify whether Unicycive completed a reverse stock split and regained compliance by July 24, 2023.
- Review subsequent Nasdaq correspondence for any extension, delisting determination, or hearing outcome.
- Assess the Company’s stockholders’ equity and financing activities, given the stated failure to meet the $5.0 million initial listing requirement.
- Review subsequent filings for potential dilution, capital-raising transactions, and the effect of any reverse stock split.